Novavax (NVAX) Misses Q4 EPS by 99c ; Offers Guidance

Novavax (NASDAQ: NVAX) reported Q4 EPS of ($1.44), $0.99 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $291 million versus the consensus estimate of $321.97 million.

GUIDANCE:

Novavax sees FY2024 revenue of $0.8-1 billion, versus the consensus of $0.97 billion.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)